TROP2 expression
|
NSCLC
|
TROP2 expression
|
NSCLC
|
DS-1062a Sensitive: C2 – Inclusion Criteria
|
DS-1062a Sensitive: C2 – Inclusion Criteria
|
TROP2 expression
|
Cervical Cancer
|
TROP2 expression
|
Cervical Cancer
|
sacituzumab govitecan-hziy Sensitive: D – Preclinical
|
sacituzumab govitecan-hziy Sensitive: D – Preclinical
|
TROP2 expression
|
Breast Cancer
|
TROP2 expression
|
Breast Cancer
|
DS-1062a Sensitive: D – Preclinical
|
DS-1062a Sensitive: D – Preclinical
|
TROP2 expression
|
HER2 Positive Breast Cancer
|
TROP2 expression
|
HER2 Positive Breast Cancer
|
neratinib Sensitive: D – Preclinical
|
neratinib Sensitive: D – Preclinical
|
TROP2 expression
|
HER2 Positive Breast Cancer
|
TROP2 expression
|
HER2 Positive Breast Cancer
|
lapatinib Sensitive: D – Preclinical
|
lapatinib Sensitive: D – Preclinical
|